Active Ingredient History
Methadone, sold under the brand names Dolophine among others, is an synthetic opioid that is used as the hydrochloride to treat pain and as maintenance therapy or to help with detoxification in people with opioid dependence. Methadone hydrochloride is a mu-agonist; a synthetic opioid analgesic with multiple actions qualitatively similar to those of morphine. Some data also indicate that methadone acts as an antagonist at the NMDA-receptor. The contribution of NMDA receptor antagonism to methadone’s efficacy is unknown. Most common adverse reactions are: lightheadedness, dizziness, sedation, nausea, vomiting, and sweating. Avoid use mixed agonist/antagonist and partial agonist opioid analgesics with DOLOPHINE because they may reduce analgesic effect of DOLOPHINE or precipitate withdrawal symptoms. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Abortion, Induced (Phase 4)
Acquired Immunodeficiency Syndrome (Phase 4)
Acute Pain (Phase 3)
Adenocarcinoma (Phase 3)
Analgesics, Opioid (Phase 4)
Anesthesia (Phase 3)
Antiretroviral Therapy, Highly Active (Phase 2)
Arrhythmias, Cardiac (Phase 4)
Back Pain (Phase 4)
Bariatric Surgery (Phase 4)
Behavior, Addictive (Phase 4)
Breast Neoplasms (Phase 1/Phase 2)
Buprenorphine (Phase 2)
Cancer Pain (Phase 3)
Candidiasis (Phase 1)
Cardiotoxicity (Phase 4)
Chronic Disease (Phase 1/Phase 2)
Chronic Pain (Phase 4)
Cocaine-Related Disorders (Phase 3)
Colonic Neoplasms (Phase 4)
Colorectal Neoplasms (Phase 1/Phase 2)
Constipation (Phase 4)
Critical Illness (Phase 1/Phase 2)
Delirium (Phase 4)
Diverticulitis, Colonic (Phase 4)
Drug Interactions (Early Phase 1)
Drugs, Investigational (Phase 4)
Esophageal Neoplasms (Phase 1/Phase 2)
Eye Neoplasms (Phase 1/Phase 2)
Fentanyl (Phase 3)
Fractures, Bone (Phase 4)
General Surgery (Phase 3)
Head and Neck Neoplasms (Phase 4)
Healthy Volunteers (Phase 1)
Hepacivirus (Phase 1)
Hepatitis (Phase 4)
Hepatitis C (Phase 3)
Hepatitis C, Chronic (Phase 4)
Heroin Dependence (Phase 4)
Herpes Zoster (Phase 3)
Hip Fractures (Phase 4)
HIV (Phase 4)
HIV Infections (Phase 4)
Ileus (Phase 4)
Immune System Diseases (Phase 2)
Infant, Premature (Phase 1/Phase 2)
Inflammation (Phase 2)
Intervertebral Disc Degeneration (Phase 1)
Intestinal Pseudo-Obstruction (Phase 4)
Kidney Failure, Chronic (Phase 3)
Kyphosis (Phase 1)
Laminectomy (Phase 4)
Low Back Pain (Phase 4)
Methadone (Phase 4)
Morphine (Phase 3)
Naltrexone (Phase 2)
Nausea (Phase 1)
Neonatal Abstinence Syndrome (Phase 4)
Neoplasms (Phase 3)
Neuralgia (Phase 4)
Neuralgia, Postherpetic (Phase 3)
Only Child (Phase 3)
Opiate Alkaloids (Phase 4)
Opiate Overdose (Phase 3)
Opiate Substitution Treatment (Phase 3)
Opioid-Related Disorders (Phase 4)
Orthopedic Procedures (Phase 3)
Otorhinolaryngologic Neoplasms (Phase 1/Phase 2)
Pain ()
Pain, Intractable (Phase 3)
Pain, Postoperative (Phase 4)
Pain, Procedural (Phase 2)
Palliative Care (Phase 2/Phase 3)
Pancreatic Neoplasms (Phase 1/Phase 2)
Patient Satisfaction (Phase 4)
Peripheral Nervous System Diseases (Phase 2)
Pharmacokinetics (Phase 4)
Polyneuropathies (Phase 2)
Postoperative Nausea and Vomiting (Phase 4)
Pregnancy (Phase 3)
Prostatic Neoplasms (Phase 1/Phase 2)
Rectal Neoplasms (Phase 4)
Scoliosis (Phase 4)
Sleep Apnea, Obstructive (Phase 2)
Sleep Wake Disorders (Phase 1)
Spinal Stenosis (Phase 4)
Spondylolisthesis (Phase 4)
Substance Withdrawal Syndrome (Phase 1)
Testicular Hydrocele (Phase 4)
Tonsillitis (Phase 2)
Tuberculosis (Phase 4)
Urinary Bladder Neoplasms (Phase 1/Phase 2)
Uterine Neoplasms (Phase 1/Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue